Sign In
Buy NMRA
$1.74
-0.0100 (-0.571%)
At Close: Jun 03, 2026
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal secu
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NMRA
11:45am, Friday, 21'st Mar 2025
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal secu
NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Neumo
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal secu
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ:NMRA).
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal secu
RADNOR, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA
07:30am, Friday, 21'st Mar 2025
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal secu
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumo
Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline
05:45am, Friday, 21'st Mar 2025
NEW YORK , March 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action secur
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA
06:45pm, Thursday, 20'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal secu
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm
06:24pm, Thursday, 20'th Mar 2025
NEW YORK , March 20, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
06:00pm, Thursday, 20'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal secu
Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – NMRA
07:15pm, Wednesday, 19'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal secu
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or tra
